Bone mineral density and breast cancer

In this study, researchers evaluated the long-term impact (over a total period of 10 years) of breast cancer and its treatment on bone mineral density, particularly after discontinuation of treatment with an aromatase inhibitor. A total of 372 patients with pre- and post-menopausal breast cancer were included in the study. Discontinuation of the aromatase inhibitor at 5 years had a significant impact on bone mineral density. Bone mineral density increased in patients weaned off the aromatase inhibitor during the first 5 years, while a decrease in bone mineral density was observed in patients without aromatase inhibitor weaning.